<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00992888</url>
  </required_header>
  <id_info>
    <org_study_id>Heliac-01</org_study_id>
    <nct_id>NCT00992888</nct_id>
  </id_info>
  <brief_title>Inflammation, Immune Activation and Portal Hypertension in Alcoholic Hepatitis</brief_title>
  <acronym>Heliac</acronym>
  <official_title>Inflammation, Immune Activation and Portal Hypertension in Alcoholic Hepatitis. A Pato-etiological Study With Focus on the Endotoxin Pathway.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the role of endotoxins and the endotoxin mediated
      immune activation pathway in patients with alcoholic hepatitis. Also, to determine the effect
      of Liver assist (liver dialyses) intervention on these parameters in patients with severe
      alcoholic hepatitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum endotoxin levels</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endotoxin activation pathway proteins</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>albumin liver dialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard medial care without dialysis</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prometheus Liver Dialysis system (Fresenius Medical Care)</intervention_name>
    <description>6 hour dialysis for 3 consecutive days</description>
    <arm_group_label>albumin liver dialysis</arm_group_label>
    <other_name>The prometheus albumin dialysis by Fresenius Medical Care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with alcoholic hepatitis based on the following criteria

          -  Alcohol intake for 6 consecutive months above 40g /day, at admission or 3 months
             earlier.

          -  Serum bilirubin level above 80 mmol/l

          -  exclusion of other types of liver disease.

          -  Liver biopsy when diagnosis is unclear.

        Exclusion Criteria:

          -  Heart failure

          -  Pregnancy

          -  non fluent danish speakers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hendrik Vilstrup, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Department of Medicine V, Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine V, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2009</study_first_submitted>
  <study_first_submitted_qc>October 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2009</study_first_posted>
  <last_update_submitted>September 14, 2011</last_update_submitted>
  <last_update_submitted_qc>September 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Thomas Damgaard Sandahl</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Alcoholic Hepatitis</keyword>
  <keyword>Alcohol</keyword>
  <keyword>Endotoxin</keyword>
  <keyword>LPS</keyword>
  <keyword>Liver dialysis</keyword>
  <keyword>Innate immunity</keyword>
  <keyword>Toll Like receptors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

